Global Parathyroid Disease Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Parathyroid Disease Treatment Market Size

• The global parathyroid disease treatment market size was valued at USD 2.57 billion in 2025and is expected to reach USD 4.25 billion by 2033, at a CAGR of 6.50% during the forecast period
• The market growth is primarily driven by the rising prevalence of parathyroid disorders, particularly hyperparathyroidism and hypoparathyroidism, supported by increasing diagnosis rates and improved awareness of calcium and endocrine-related diseases in aging populations
• Furthermore, advancements in treatment approaches, including minimally invasive parathyroidectomy, improved imaging techniques for gland localization, and expanding use of calcimimetic drugs and hormone replacement therapies, are enhancing clinical outcomes and driving strong adoption across healthcare systems, thereby significantly boosting the industry's growth

Parathyroid Disease Treatment Market Analysis

• Parathyroid disease treatment includes pharmacological and supportive therapies used to manage calcium imbalance disorders such as hyperparathyroidism and hypoparathyroidism, with increasing reliance on targeted drug therapies and hormone regulation approaches to control disease progression and reduce complications in both chronic and acute cases
• The escalating demand for parathyroid disease treatment is primarily fueled by the rising prevalence of endocrine disorders, increasing cases of chronic kidney disease-associated secondary hyperparathyroidism, and growing adoption of long-term medication-based management strategies supported by improved diagnostic awareness and screening programs
• North America dominated the parathyroid disease treatment market with the largest revenue share of 39.4% in 2025, supported by advanced healthcare infrastructure, high treatment accessibility, strong reimbursement frameworks, and widespread use of novel pharmacological therapies across specialized endocrine care centers in the U.S.
• Asia-Pacific is expected to be the fastest growing region in the parathyroid disease treatment market during the forecast period due to improving healthcare infrastructure, rising patient awareness, expanding access to endocrine disorder treatments, and increasing prevalence of vitamin D deficiency and kidney-related complications
• Calcimimetics segment dominated the parathyroid disease treatment market with a market share of 44.8% in 2025, driven by their strong efficacy in regulating parathyroid hormone levels, especially in secondary hyperparathyroidism patients, along with growing clinical preference as a first-line pharmacological treatment option in chronic management protocols

Report Scope and Parathyroid Disease Treatment Market Segmentation

Parathyroid Disease Treatment Market Trends

“Expanding Shift Toward Targeted Pharmacological and Precision Endocrine Therapies”

• A significant and accelerating trend in the global parathyroid disease treatment market is the growing reliance on targeted pharmacological therapies such as calcimimetics and hormone regulation drugs, improving long-term control of parathyroid hormone levels in chronic patients
• For instance, Cinacalcet-based calcimimetic therapies are widely used in secondary hyperparathyroidism management, particularly in dialysis patients requiring sustained biochemical control of calcium and phosphate balance
• Advancements in precision endocrine medicine are enabling more personalized treatment approaches, with therapies increasingly tailored based on patient-specific hormone levels, kidney function, and disease severity progression patterns
• The integration of advanced diagnostic imaging and biochemical monitoring with treatment protocols is improving therapy optimization, allowing clinicians to adjust dosing strategies and improve patient outcomes more effectively
• This shift toward targeted and patient-specific endocrine treatment is reshaping clinical expectations, leading companies such as Amgen and other specialty pharma players to focus on next-generation calcium-regulating therapies with improved safety profiles
• The demand for advanced, long-term management solutions for parathyroid disorders is growing steadily across hospitals and specialty clinics, as healthcare providers prioritize non-surgical and sustained disease control approaches
• The growing adoption of digital health tools for chronic endocrine disorder monitoring is supporting remote patient tracking and improving adherence to long-term parathyroid treatment regimens

Parathyroid Disease Treatment Market Dynamics

Driver

“Rising Burden of Chronic Kidney Disease and Endocrine Disorders Driving Treatment Demand”

• The increasing prevalence of chronic kidney disease and associated secondary hyperparathyroidism, along with rising endocrine disorder cases, is a major driver fueling the demand for parathyroid disease treatment worldwide
• For instance, growing dialysis patient populations are significantly contributing to higher usage of calcimimetics and hormone-based therapies for long-term management of parathyroid hormone imbalance
• Improved diagnostic rates and early detection of calcium metabolism disorders are enabling timely treatment initiation, thereby increasing overall market uptake for both pharmacological and supportive therapies
• Furthermore, aging populations are more prone to parathyroid dysfunction, driving sustained demand for long-term disease management solutions across healthcare systems globally
• The increasing adoption of advanced treatment protocols in hospitals and specialty clinics is further supporting market growth by improving accessibility and standardization of care pathways
• Rising healthcare expenditure and expanded insurance coverage for endocrine disorder treatments are also enabling better patient access to advanced therapies in developed markets
• Growing physician awareness and guideline-based treatment adoption are improving early intervention rates, thereby expanding the treated patient pool significantly

Restraint/Challenge

“Long-Term Therapy Dependence and Limited Treatment Accessibility in Emerging Regions”

• A key challenge restraining the market is the need for prolonged and continuous treatment regimens, which increases patient dependency on lifelong pharmacological management and reduces treatment compliance over time
• For instance, calcimimetic therapies often require long-term administration with regular monitoring, creating adherence challenges particularly in patients with complex comorbid conditions
• Limited awareness and underdiagnosis of parathyroid disorders in low- and middle-income regions further restrict early treatment adoption and reduce overall market penetration
• In addition, high treatment costs associated with advanced pharmacological therapies and hormone replacement options can limit accessibility for uninsured or economically constrained patient populations
• Addressing these challenges through improved affordability, expanded diagnostic outreach, and simplified treatment protocols will be essential for sustained global market expansion
• Variability in reimbursement policies across different healthcare systems further creates inconsistencies in treatment accessibility and delays initiation of optimal therapy in several regions
• The requirement for continuous biochemical monitoring and specialist supervision also increases overall treatment complexity, limiting widespread adoption in resource-constrained healthcare settings

Parathyroid Disease Treatment Market Scope

The market is segmented on the basis of treatment, route of administration, end-users, and distribution channel.

• By Treatment

On the basis of treatment, the parathyroid disease treatment market is segmented into calcimimetics, bisphosphonates, plicamycin, hormone replacement therapy, and others. The calcimimetics segment dominated the market with the largest revenue share of 44.8% in 2025, driven by its strong clinical effectiveness in regulating parathyroid hormone (PTH) levels, particularly in secondary hyperparathyroidism patients with chronic kidney disease. These drugs are widely preferred as first-line pharmacological therapy due to their ability to directly modulate calcium-sensing receptors, improving biochemical control. Growing adoption in dialysis populations and strong physician preference for long-term disease management solutions further supports dominance. In addition, established availability and guideline-backed usage across major healthcare systems reinforce its leading position.

The hormone replacement therapy segment is expected to witness the fastest growth rate of 11.9% from 2026 to 2033, fueled by increasing cases of hypoparathyroidism requiring lifelong calcium and vitamin D regulation. Rising awareness of long-term endocrine management and improved formulation stability of parathyroid hormone analogs are boosting adoption. Furthermore, ongoing clinical advancements in recombinant PTH therapies are improving treatment precision and safety outcomes. Expanding access to specialized endocrine care and increasing patient preference for physiologic hormone-based treatment approaches are accelerating growth in this segment.

• By Route of Administration

On the basis of route of administration, the market is segmented into oral and parenteral. The oral segment dominated the market with the largest revenue share of 58.6% in 2025, driven by the widespread use of oral calcimimetics and bisphosphonates for long-term outpatient management of parathyroid disorders. Oral therapies offer high patient compliance, ease of administration, and reduced dependency on hospital visits, making them highly suitable for chronic disease management. Strong preference among physicians for non-invasive treatment options further supports dominance. In addition, cost-effectiveness compared to injectable therapies contributes to higher adoption in both developed and emerging healthcare systems.

The parenteral segment is expected to witness the fastest growth rate of 10.4% from 2026 to 2033, driven by increasing use of injectable hormone replacement therapies and hospital-based treatments for severe or complex cases. Parenteral administration ensures faster bioavailability and precise dosing control, which is critical in acute or refractory parathyroid conditions. Rising hospital admissions for endocrine complications and growing use of biologic therapies are further accelerating demand. Moreover, advancements in injectable PTH formulations are improving patient outcomes and expanding clinical adoption.

• By End-Users

On the basis of end-users, the market is segmented into hospitals, homecare, specialty centres, and others. The hospitals segment dominated the market with the largest revenue share of 49.3% in 2025, driven by high patient inflow for diagnosis, surgical evaluation, and initiation of pharmacological therapy under specialist supervision. Hospitals remain the primary setting for managing moderate to severe parathyroid disorders, especially in patients with comorbid chronic kidney disease. Availability of advanced diagnostic infrastructure and multidisciplinary endocrine teams further supports dominance. In addition, reimbursement coverage for hospital-based treatment enhances patient access and treatment adherence.

The specialty centres segment is expected to witness the fastest growth rate of 12.1% from 2026 to 2033, fueled by increasing demand for specialized endocrine care and precision-based treatment protocols. These centres offer focused expertise in parathyroid disorders, enabling better disease monitoring and personalized therapy adjustments. Rising referrals from general hospitals and growing patient preference for specialized consultation are supporting expansion. Furthermore, integration of advanced diagnostic tools and long-term disease management programs is accelerating adoption in this segment.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment dominated the market with the largest revenue share of 52.7% in 2025, driven by strong integration with inpatient and outpatient hospital treatment pathways. Most calcimimetics and injectable therapies are prescribed and dispensed directly through hospital pharmacies to ensure controlled dosing and monitoring. High reliance on physician-led prescription management and immediate drug availability for hospitalized patients further supports dominance. In addition, institutional procurement systems ensure consistent supply for chronic endocrine disorder treatments.

The online pharmacy segment is expected to witness the fastest growth rate of 14.6% from 2026 to 2033, fueled by rising digital healthcare adoption and increasing demand for home delivery of chronic medications. Patients with long-term parathyroid conditions prefer online platforms for convenience, cost savings, and prescription refill automation. Expansion of e-pharmacy regulations and improved digital prescription integration are further accelerating growth. In addition, increasing penetration of telemedicine services is strengthening online pharmacy adoption in both urban and semi-urban regions.

Parathyroid Disease Treatment Market Regional Analysis

• North America dominated the parathyroid disease treatment market with the largest revenue share of 39.4% in 2025, supported by advanced healthcare infrastructure, high treatment accessibility, strong reimbursement frameworks, and widespread use of novel pharmacological therapies across specialized endocrine care centers in the U.S.
• Healthcare providers in the region widely prefer calcimimetics and hormone-based therapies supported by established clinical guidelines, advanced diagnostic infrastructure, and early disease detection practices across hospitals and specialty clinics.
• This widespread adoption is further supported by high healthcare expenditure, strong reimbursement coverage, and the presence of leading pharmaceutical companies focusing on innovative parathyroid disease management therapies, establishing North America as the most advanced treatment market globally.

U.S. Parathyroid Disease Treatment Market Insight

The U.S. parathyroid disease treatment market captured the largest revenue share of 81% within North America in 2025, driven by a high burden of chronic kidney disease–associated secondary hyperparathyroidism and strong adoption of advanced endocrine therapies. Patients in the country increasingly benefit from early diagnosis and access to specialized endocrinology and nephrology care centers, enabling timely use of calcimimetics, bisphosphonates, and hormone replacement therapies. The market growth is further supported by robust healthcare infrastructure, high insurance coverage, and strong presence of leading pharmaceutical companies focusing on innovative calcium regulation and long-term disease management solutions.

Europe Parathyroid Disease Treatment Market Insight

The Europe parathyroid disease treatment market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by rising prevalence of endocrine disorders and increasing cases linked to chronic kidney disease. The region benefits from well-established public healthcare systems and strong adoption of evidence-based treatment protocols, particularly for calcimimetics and hormone replacement therapies. In addition, growing awareness of early diagnosis and long-term disease management is supporting wider treatment uptake across hospitals and specialty endocrine clinics in both urban and semi-urban areas.

U.K. Parathyroid Disease Treatment Market Insight

The U.K. parathyroid disease treatment market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing diagnosis rates of parathyroid disorders and rising demand for advanced endocrine care services. Growing reliance on hospital-based treatment pathways and specialist endocrinology units is supporting higher adoption of pharmacological therapies such as calcimimetics and bisphosphonates. Moreover, strong public healthcare access, structured treatment guidelines, and rising awareness of calcium imbalance disorders are further stimulating market growth across the country.

Germany Parathyroid Disease Treatment Market Insight

The Germany parathyroid disease treatment market is expected to expand at a considerable CAGR during the forecast period, fueled by rising incidence of chronic kidney disease and increasing focus on precision-based endocrine therapies. Germany’s advanced healthcare infrastructure supports strong utilization of pharmacological treatments such as calcimimetics and hormone replacement therapy for long-term disease control. Furthermore, strong clinical research activity and high adoption of guideline-driven treatment approaches are improving patient outcomes and supporting steady market expansion.

Asia-Pacific Parathyroid Disease Treatment Market Insight

The Asia-Pacific parathyroid disease treatment market is poised to grow at the fastest CAGR of 12.8% during the forecast period of 2026 to 2033, driven by rising healthcare awareness, increasing prevalence of kidney-related disorders, and expanding access to endocrine care. Rapid urbanization and improving healthcare infrastructure in countries such as China, Japan, and India are significantly supporting diagnosis and treatment uptake. In addition, growing affordability of pharmacological therapies and government initiatives to strengthen chronic disease management are accelerating adoption across both public and private healthcare systems.

Japan Parathyroid Disease Treatment Market Insight

The Japan parathyroid disease treatment market is gaining momentum due to its aging population, high prevalence of chronic metabolic disorders, and strong healthcare system focused on early disease detection. Patients increasingly benefit from advanced diagnostic tools and structured endocrine care pathways, leading to higher adoption of hormone replacement therapies and calcimimetics. Moreover, Japan’s emphasis on precision medicine and long-term chronic disease management is supporting integration of advanced pharmacological treatments into routine clinical practice.

India Parathyroid Disease Treatment Market Insight

The India parathyroid disease treatment market accounted for the largest revenue share in Asia-Pacific in 2025, driven by a rapidly growing patient population with kidney-related complications and improving diagnostic capabilities. Increasing access to affordable pharmacological therapies and expansion of specialty endocrine and nephrology care centers are supporting treatment adoption across urban and semi-urban regions. Furthermore, rising healthcare awareness, government initiatives for chronic disease management, and growing hospital infrastructure development are key factors propelling sustained market growth in India.

Parathyroid Disease Treatment Market Share

The Parathyroid Disease Treatment industry is primarily led by well-established companies, including:

• Amgen Inc., (U.S.)
• Novartis AG, (Switzerland)
• Merck & Co., Inc., (U.S.)
• Pfizer Inc., (U.S.)
• AbbVie Inc., (U.S.)
• Sanofi (France)
• Bristol Myers Squibb Company, (U.S.)
• Eli Lilly and Company, (U.S.)
• Takeda Pharmaceutical Company Limited, (Japan)
• AstraZeneca PLC, (U.K.)
• F. Hoffmann-La Roche Ltd, (Switzerland)
• GSK plc, (U.K.)
• Teva Pharmaceutical Industries Limited, (Israel)
• Sun Pharmaceutical Industries Limited, (India)
• Dr. Reddy’s Laboratories Limited, (India)
• Hikma Pharmaceuticals PLC, (U.K.)
• Amneal Pharmaceuticals, Inc., (U.S.)
• Kyowa Kirin Co., Ltd., (Japan)
• Ipsen S.A., (France)
• Recordati S.p.A., (Italy)

What are the Recent Developments in Global Parathyroid Disease Treatment Market?

• In December 2025, Takeda confirmed the closure of the NATPARA U.S. Special Use Program, effectively ending access to remaining supplies of the therapy and reinforcing the global urgency for new parathyroid hormone replacement solutions
• In August 2024, Ascendis Pharma received FDA approval for Yorvipath (palopegteriparatide), a first-in-class long-acting parathyroid hormone replacement therapy for adults with hypoparathyroidism, representing a major advancement in long-term endocrine disorder management by reducing dependence on daily calcium and active vitamin D supplementation
• In May 2024, the U.S. FDA extended its review timeline for Ascendis Pharma’s TransCon PTH therapy, highlighting the complexity of evaluating novel parathyroid hormone replacement treatments and the need for additional manufacturing and clinical validation data before final approval
• In April 2023, Ascendis Pharma reported continued regulatory and clinical progress for TransCon PTH (palopegteriparatide), an investigational long-acting parathyroid hormone therapy for hypoparathyroidism, highlighting its potential to replace conventional calcium and vitamin D–based standard care
• In November 2022, Takeda announced plans to discontinue NATPAR/NATPARA manufacturing globally due to persistent production constraints and supply limitations, accelerating industry focus on next-generation recombinant and long-acting parathyroid hormone therapies

SKU-54163